It has been previously shown that the administration of an anti-Sema4D antibody inhibits neuroinflammation during EAE development (24, 45) and is protective against bone loss in a mouse model of postmenopausal osteoporosis (15). Here, SEMA4D is linked to postmenopausal osteoporosis.